Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

SUMMARY: In a phase 2 study, continued denosumab treatment for up to 8 years was associated with continued gains in bone mineral density and persistent reductions in bone turnover markers. Denosumab treatment was well tolerated throughout the 8-year study. INTRODUCTION: The purpose of this study is...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: McClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., Miller, P. D.
Format: Artigo
Idioma:Inglês
Publicat: Springer-Verlag 2012
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3536967/
https://ncbi.nlm.nih.gov/pubmed/22776860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-012-2052-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars